Lishan Aklog MD
About
Lishan Aklog MD is from New York City Metropolitan Area. Lishan is currently Vice Chair, Board Payment Committee at AdvaMed. Lishan also works as Vice Chair, Payment at AdvaMedDx, a job Lishan has held since Jun 2025. Another title Lishan currently holds is Board Member at AdvaMedDx. In Lishan's previous role as a Audit Committee Member at ContraFect Corp, Lishan worked in until Nov 2023. Prior to joining ContraFect Corp, Lishan was a Member, Board of Directors at ContraFect Corp and held the position of Member, Board of Directors at New York City Metropolitan Area. Prior to that, Lishan was a Chairman at HealthChain, based in Greater New York City Area from Feb 2019 to Dec 2021. Lishan started working as Audit Committee Chair at Viveon Health Acquisition Corp. in Norcross, Georgia, United States in Sep 2020. From Sep 2020 to Apr 2021, Lishan was Member, Board of Directors at Viveon Health Acquisition Corp., based in Norcross, Georgia, United States. Prior to that, Lishan was a Chairman, CTO and Co-Founder at Vortex Medical, Inc, based in Norwell, MA from Mar 2008 to Oct 2012.
Lishan Aklog MD's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
Lishan Aklog MD's current jobs
The Advanced Medical Technology Association (AdvaMed), is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies. The Association acts as the common voice for companies producing medical devices, diagnostic products and digital health technologies. AdvaMed promotes competitive policies that foster the highest ethical standards, rapid product approvals, appropriate reimbursement, and access to international markets. AdvaMed has created a policy framework that, when enacted, will help preserve our leadership and foster future growth and innovation
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing. For more information, please visit www.luciddx.com or www.esoguard.com.
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure™ Esophageal Ablation Device with Caldus™ Technology, which complements EsoGuard and EsoCheck, the NextFlo™ Intravenous Infusion Set, and well as multiple other products and projects. For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube.
Pavilion Medical Innovations is a medical device incubator established by Pavilion Holding Group, Catalyst Healthcare Ventures and Dr. Al Chin. It has developed a pipeline of over a dozen innovative products in various stages towards commercialization. It has spun out three portfolio companies - Saphena Medical Inc., Kaleidoscope Medical LLC and Cruzar Medical Inc.
Pavilion Holding Group was founded to build a portfolio of medical device companies which provide commercially successful, innovative tools to alleviate to human suffering. Its portfolio companies are built and operate using a contrarian model focused on rapidly bringing cutting edge products into large markets. Its unique virtual business model with outsourced best-in-class process expertise maximizes operational and capital efficiency preserving founder and investor equity and facilitating strategic partnerships or acquisitions. PHG's first company, Vortex Medical, Inc, progressed from a modest initial capitalization round, through successful commercialization to acquisition by Angiodynamics, Inc in less than five years, providing its early investors with an attractive return. PHG created its medical device incubator, Pavilion Medical Innovations in 2009 and has spun out three additional companies based on the same capital and time efficient model - Saphena Medical Inc., Kaleidoscope Medical LLC and Cruzar Medical Inc.
Lishan Aklog MD's past jobs
ContraFect (Nasdaq: CFRX) is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. CFRX intends to address life threatening infections using it's therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. CFRX believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. It's initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.
HealthChain is utilizing blockchain technology to revolutionize the medical device industry. By using blockchain to facilitate better collaboration between medical device companies and hospitals around the common goal of reliable and timely delivery of devices to patients. HealthChain solves the problem of the outdated, time sensitive and expensive medical device supply chain currently in place.
Viveon Health Acquisition Corp. (Nasdaq: VHAQ) is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It is the Company’s intention to pursue prospective targets that are focused on the regenerative medicine, spine and orthopedic industry in the United States and other developed countries.
Vortex Medical was founded by Pavilion Holding Group to develop an innovative endovascular method and device (AngioVac) for the en bloc removal of undesirable intravascular material including venous thromboembolism. It moved rapidly from a single modest capitalization round through regulatory clearance and successful commercialization of the AngioVac device in less than 5 years. It was acquired by Angiodynamics in October 2012 in a deal valued at $55 million with additional earn-out payments over 10 years.